In Vivo Diagnostic Or In Vivo Test Agent Which Contains An Additional Ingredient To Reduce The Toxicity Or Side Effects Of The Active Ingredient Patents (Class 424/900)
-
Patent number: 8455196Abstract: The preset invention relates to a biomarker for identifying the subgroup of early-stage lung adenocarcinoma patients in early-stage non-small cell lung cancer (NSCLC), which is T-lymphokine-activated killer cell-originated protein kinase (TOPK), and a therapeutic target for lung cancer.Type: GrantFiled: May 23, 2012Date of Patent: June 4, 2013Inventor: Jin-Mei Lai
-
Patent number: 6723527Abstract: Disclosed are methods for assessment of the ability of substances to ameliorate the toxic-effects of compounds based on a lymphocyte culture assay. The lymphocyte assay is a repeatable and quantitative assay for lymphocyte growth in a chemically defined media in which specific compounds with potential toxicity and substances with potential abilities to ameliorate the toxicity can be added to determine specific and individualized requirements for such substances. Also disclosed are methods for ameliorating side-effects by administering to a patient undergoing therapy with a drug that has a toxic-effect, a substance identified by the methods of the invention. Further provided is a composition that ameliorates the toxic-effect of the statin family of drugs. Methods and processes for partially purifying and/or isolating this composition are also provided.Type: GrantFiled: October 26, 2001Date of Patent: April 20, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Flora H. Pettit, William Shive
-
Patent number: 6566350Abstract: An object of the present invention is to provide a stable pharmaceutical composition for topical administration comprising minocycline as an active ingredient. According to the present invention, there is provided a pharmaceutical composition for topical administration comprising minocycline or a physiologically acceptable salt thereof in an oleaginous base.Type: GrantFiled: May 21, 2001Date of Patent: May 20, 2003Assignee: Showa Yakuhin Kako Co., Ltd.Inventors: Kazuhiro Ono, Hidenari Sakaguchi, Ikuto Hayakawa
-
Publication number: 20010002249Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: ApplicationFiled: January 18, 2001Publication date: May 31, 2001Applicant: Praecis Pharmaceuticals IncorporatedInventor: Marc B. Garnick
-
Patent number: 5965131Abstract: An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.Type: GrantFiled: October 9, 1996Date of Patent: October 12, 1999Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, Serengulam V. Govindan, Habibe Karacay
-
Patent number: 5958408Abstract: An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.Type: GrantFiled: November 17, 1997Date of Patent: September 28, 1999Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, Serengulam V. Govindan, Habibe Karacay
-
Patent number: 5939045Abstract: An organic bismuth derivative represented by formula (I) or its salt: ?wherein X.sup.1 is YNR.sup.1 R.sup.2 (wherein Y is --SO.sub.2 -- or --C(O)--, R.sup.1 is a C.sub.3-6 alkyl group which have from 2 to 5 hydroxyl groups which may be protected, and R.sup.2 is a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.1-5 acyl group which may have from 1 to 5 hydroxyl groups which may be protected, or R.sup.1 and R.sup.2, together with each other, represent a C.sub.2-6 cyclic alkylene which may have from 1 to 4 hydroxyl groups which may be protected), and each of X.sup.2 and X.sup.3 is, independently of each other, a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkylsulfonyl group, a C.sub.1-4 alkylcarbonyl group, a nitro group, a cyano group or the same as defined for X.sup.1 !.Type: GrantFiled: July 18, 1997Date of Patent: August 17, 1999Assignee: Nissan Chemical Industries, Ltd.Inventors: Hitomi Suzuki, Keizo Tanikawa, Katsuaki Miyaji, Nobuhiro Suzuki
-
Patent number: 5730953Abstract: tris(substituted phenyl) bismuth compounds of formula (I) and pharmaceutically acceptable salts thereof are useful x-ray radiographic imaging agents: ##STR1## wherein X.sub.1, X.sub.2 and X.sub.3 are as defined in the specification.Type: GrantFiled: March 19, 1996Date of Patent: March 24, 1998Assignee: Nissan Chemical Industries, Ltd.Inventors: Hitomi Suzuki, Koichi Maeda, Keizo Tanikawa, Katsuaki Miyaji
-
Patent number: 5702682Abstract: Disclosed is a method for providing radiopacity to a medical device comprising incorporating in said medical device metal-cation salt of anionic polymer, wherein the metal has atomic weight greater than about 40; radiopaque medical devices comprising the essentially water-insoluble metal-cation salts of anionic polymers; and a method for carrying out x-ray diagnostic procedures comprising administering to a subject a contrast agent comprised of the essentially water-insoluble metal-cation salts of anionic polymer.Type: GrantFiled: December 1, 1995Date of Patent: December 30, 1997Assignee: Hercules IncorporatedInventor: Samuel Anthony Thompson
-
Patent number: 5643551Abstract: A method for initiating metastasis of human tumor cells under experimental conditions is provided. Immunocompromised non-human mammals having a viable, xenogeneic organ or tissue are used as a host for human tumor cells. The cells are introduced into the chimeric animal after the solid tissue is implanted and are then able to grow and metastasize as they would in situ. Therapeutic regimens may be evaluated in this system to determine efficacy against metastatic processes.Type: GrantFiled: October 26, 1994Date of Patent: July 1, 1997Assignee: Systemix, Inc.Inventors: Reiko Namikawa, Seishi Kyoizumi, Emilya Shtivelman, Joseph M. McCune
-
Patent number: 5571498Abstract: Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic chelator having a C.sub.10 -C.sub.30 unsaturated aliphatic group. The emulsions are very stable and therapeutically acceptable for intravenous administration to enhance MRI.Type: GrantFiled: June 2, 1994Date of Patent: November 5, 1996Assignee: HemaGen/PFCInventors: William P. Cacheris, Robert J. Kaufman, Thomas J. Richard, Raymond C. Grabiak
-
Patent number: 5516503Abstract: A diagnostic composition comprising a binuclear complex between a polyaminopolycarboxylic ligand, such as diethylene triamine pentacetic acid, a paramagnetic metal such as Gd and an endogenous metal such as Ca, optionally mixed with the mononuclear complex of the same paramagnetic metal and the same ligand. This composition can be used as a contrasting agent in magnetic resonance imaging.Type: GrantFiled: November 7, 1994Date of Patent: May 14, 1996Assignee: Guerbet S.A.Inventors: Corinne Bourgouin, Gerard Desplanches, Michele Lecayon
-
Patent number: 5476646Abstract: Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a nonionic x-ray producing agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.Type: GrantFiled: April 21, 1994Date of Patent: December 19, 1995Assignee: Sterling Winthrop Inc.Inventors: Stephen B. Ruddy, Gregory L. McIntire, Mary E. Roberts, John L. Toner
-
Patent number: RE36418Abstract: The physiological acceptability of contrast media, especially media for use in angiography, may be enhanced by inclusion of sub-plasma levels of sodium and calcium and, optionally, potassium and/or magnesium, for example 30 mM Na, 0.15 mM Ca, 0.9 mM K and 0.1 mM Mg.Type: GrantFiled: March 15, 1996Date of Patent: November 30, 1999Assignee: Nycomed Imaging ASInventors: Torsten Almen, Lars Baath, Per Jynge, Audun Nesheim Oksendal